Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Citius Pharmaceuticals Inc. (NASDAQ: CTXR).

Full DD Report for CTXR

You must become a subscriber to view this report.


Recent News from (NASDAQ: CTXR)

Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing
Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing Canada NewsWire CRANFORD, N.J., Dec. 10, 2018 Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation CRANFORD, ...
Source: Canada Newswire
Date: December, 10 2018 08:35
Citius Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
CRANFORD, N.J. , Oct. 25, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Executive Chairman , Leon...
Source: PR Newswire
Date: October, 25 2018 08:00
Citius Announces The Publication Of European Patent For Mino-Lok®
CRANFORD, N.J. , Sept. 27, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, received official notification from MD Anderson Cancer Center ("MDA...
Source: PR Newswire
Date: September, 27 2018 08:00
Stocks To Watch: Time To Talk Valuation
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The stock market could get a bit of a test as traders return back to their desks fo...
Source: SeekingAlpha
Date: September, 01 2018 08:28
Midday Gainers / Losers (08/27/2018)
Gainers:  TIS +37% . HMNY +37% . CRON +21% . TLRY +20% . ALNY +17% . JMEI +17% . CTXR +18% . LAC +15% . KONE +14% . LEVB +13% . More news on: Orchids Paper Products Company, Helios and Matheson Analytics, Inc., Cronos Group, Inc., Stocks on the move, , ...
Source: SeekingAlpha
Date: August, 27 2018 12:48
Daily Insider Ratings Round Up 8/15/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...
Source: SeekingAlpha
Date: August, 20 2018 05:38
Citius Pharmaceuticals Successfully Raises $10 Million
CRANFORD, N.J. , Aug. 15, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company completed the largest capital raise i...
Source: PR Newswire
Date: August, 15 2018 08:00
Citius Announces Closing of $10.0 Million Underwritten Offering Priced At-the-Market
CRANFORD, N.J. , Aug. 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced underwritten at-the-market offerin...
Source: PR Newswire
Date: August, 13 2018 17:00
Midday Gainers / Losers (08/10/2018)
Gainers: TMSR +50% . AWX +48% . MDLY +45% . TTD +35% . CORI +22% . SNOA +21% . OSTK +19% . PVG +18% . CKPT +18% . TRUE +17% . More news on: TMSR Holding Co., Ltd., Avalon Holdings Corporation, Medley Management, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 10 2018 12:38
Pot Stocks & Biotech Stocks to Watch in 2018 & Beyond
CORAL GABLES, FL / ACCESSWIRE / August 9, 2018 / Healthcare and biotechnology indexes are in the green this morning along with major markets pushing higher. The iShares Biotechnology Index (IBB) has risen an impressive 8.9% this year and has begun turning toward its 52-week high. Lately m...
Source: ACCESSWIRE IA
Date: August, 09 2018 13:55

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-081.651.501.651.50109,907
2018-05-182.302.322.32522.266,632
2018-05-172.302.322.32522.266,632

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-111,6003,67343.5611Short
2018-12-102,74518,38514.9306Cover
2018-12-071,5132,91851.8506Short
2018-12-063,63031,17611.6436Cover
2018-12-0418,74131,20660.0558Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTXR.


About Citius Pharmaceuticals Inc. (NASDAQ: CTXR)

Logo for Citius Pharmaceuticals Inc. (NASDAQ: CTXR)

lt p gt Citius Pharmaceuticals, Inc., company was founded in and is based in Cranford, NJ. Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. lt /p gt

 

Contact Information

 

 

Current Management

  • Leonard Mazur / Secretary
  • Myron Holubiak / CEO, President
    • Myron Holubiak is the President, Chief Executive Officer and a Director of the Company. Mr. Holubiak has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. Roche , a major researchbased pharmaceutical company, from December to August . Prior to that, he held sales and marketing positions at Roche during his year tenure. Since July , Mr. Holubiak has served as a member of the board of directors of Assembly Biosciences, Inc. Assembly Nasdaq: ASMB and its predecessor Ventrus Biosciences, Inc. Ventrus . Assembly is a biopharmaceutical company developing innovative treatments for hepatitis B virus infection HBV and C. difficileassociated diarrhea CDAD . Ventrus developed treatment for hemorrhoids, however, phase clinical trials of their compound which was a new molecular entity and not previously approved HC/Lido failed to demonstrate efficacy. After Ventrus merger with Assembly, this program was discontinued. In March, , Mr. Holubiak founded LeonardMeron Biosciences, Inc. LMB , the Company s whollyowned subsidiary, and he served as the Chief Executive Officer and President of LMB until March, . In addition, Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. Mr. Holubiak received a B.S. in Molecular Biology and Biophysics from the University of Pittsburgh.
  • Leonard Mazur / Executive Chairman
  • Suren Dutia /
  • Dr. Eugene Holuka /
  • Dr. William Kane /
  • Howard Safir /
  • Carol Webb /

Current Share Structure

  • Market Cap: $32,144,352 - 03/09/2018
  • Authorized: 200,000,000 - 03/01/2018
  • Issue and Outstanding: 9,982,718 - 03/01/2018

 


Recent Filings from (NASDAQ: CTXR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 27 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 27 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 26 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 26 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 20 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: April, 20 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 11 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 11 2018

 

 


Daily Technical Chart for (NASDAQ: CTXR)

Daily Technical Chart for (NASDAQ: CTXR)


Stay tuned for daily updates and more on (NASDAQ: CTXR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CTXR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTXR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CTXR and does not buy, sell, or trade any shares of CTXR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/